Cart
sales@molnova.com
PAL-4
CAS No. 2609594-35-4
PAL-4( 1H-1,2,4-Triazol-5-amine, 3-[[(4-chlorophenyl)methyl]thio]-1-[(2,3-dihydro-5-benzofuranyl)sulfonyl]- )
Catalog No. M28869 CAS No. 2609594-35-4
PAL-4 stimulates the activity of LYPLAL1, a poorly characterized serine hydrolase with complex genetic links to human metabolic traits.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 215 | In Stock |
|
| 5MG | 192 | In Stock |
|
| 10MG | 283 | In Stock |
|
| 25MG | 452 | In Stock |
|
| 50MG | 631 | In Stock |
|
| 100MG | 848 | In Stock |
|
| 200MG | 1107 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePAL-4
-
NoteResearch use only, not for human use.
-
Brief DescriptionPAL-4 stimulates the activity of LYPLAL1, a poorly characterized serine hydrolase with complex genetic links to human metabolic traits.
-
DescriptionPAL-4 stimulates the activity of LYPLAL1, a poorly characterized serine hydrolase with complex genetic links to human metabolic traits.
-
In Vitro——
-
In Vivo——
-
Synonyms1H-1,2,4-Triazol-5-amine, 3-[[(4-chlorophenyl)methyl]thio]-1-[(2,3-dihydro-5-benzofuranyl)sulfonyl]-
-
PathwayOthers
-
TargetOther Targets
-
Recptorglucocerebrosidase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2609594-35-4
-
Formula Weight422.91
-
Molecular FormulaC17H15ClN4O3S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNc1nc(SCc(cc2)ccc2Cl)nn1S(c(cc1)cc2c1OCC2)(=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Marugan JJ, et al. Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity. J Med Chem. 2011 Feb 24;54(4):1033-58.
molnova catalog
related products
-
Dehydroepiandrostero...
Prasterone sulfate is a HSD11B1 expression inhibitor.
-
β-Amyloid(40-1)
β-Amyloid (40-1) is a biological active peptide. (non-toxic reverse fragment Aβ(40–1)
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
